

Prediabetes Weekly Newsletter



PCOS and Insulin Resistance: What Studies Show, Proven Treatments, and Lifestyle Wins

For women navigating prediabetes – the metabolic overlap you need to know.

Hi Reader,

You've likely heard PCOS called a "hormone disorder." But for our prediabetes community - especially women - it's far more: a metabolic powerhouse where insulin resistance (IR) drives 70% of cases, amplifying your prediabetes risk 3-5x.

Stuck cycles of high insulin fuel excess androgens, ovarian chaos, and stubborn belly fat. The good news? Targeted action reverses this - not just symptoms, but the root.

Today, we unpack what studies actually show, effective treatments, and best lifestyle shifts for insulin sensitivity. Evidence from 2025-2026 trials guides every point.

Let's reclaim metabolic control.

What Studies Actually Show: IR as PCOS's Core Engine

Insulin resistance isn't a side effect - it's foundational. Up to 70% of PCOS patients have IR, even lean ones. Hyperinsulinemia overstimulates ovarian theca cells, spiking androgens like testosterone by 2-3x and halting ovulation.

2025-2026 research sharpens the picture:

- Phenotype differences: IR hits hardest in classic PCOS (phenotype A: obesity + hyperandrogenism), with HOMA-IR scores 50% higher than lean phenotypes.
- Ovarian focus: A February 2026 mouse study pinpointed low kisspeptin in granulosa cells causing local ovarian IR - wrecked mitochondria, high ROS, blocked PI3K/AKT/GLUT4 signaling. Kisspeptin fixed it all.

- Gut & inflammation: Microbiome dysbiosis worsens systemic IR; East Asians show severe IR at lower BMIs.

Prediabetes parallel? PCOS accelerates your progression to type 2 diabetes by 2-4x without intervention. But studies scream reversibility - lifestyle cuts risk 50%+, mirroring DPP trial wins.

Proven Treatments: Targeting IR Head-On

No one-size-fits-all, but insulin sensitizers lead. Guidelines prioritize metabolic fixes before symptom bandaids.

Pharmacology Stars:

- Metformin (500-2000mg/day): Gold standard AMPK activator. Drops HOMA-IR 20-30%, restores cycles in 50%. Caveat: GI upset in 25%.
- Inositols (myo- 2-4g + D-chiro- 50-100mg): "Vitamin-like" messengers rival metformin – 60% ovulation rate boost, no side effects.
- Emerging GLP-1s (semaglutide/liraglutide): Weight loss + direct IR improvement. 2025 trials: superior to metformin for visceral fat and androgens.

New Horizons (2026 Trials):

- Kisspeptin agonists for ovarian IR.
- SGLT2s like empagliflozin for glycosuria-driven sensitivity.
- Berberine: Natural AMPK mimic with anti-androgen punch.

Combine with lifestyle for 80% metabolic response – studies confirm synergy.

Best Lifestyle Changes: High-Leverage Wins for Sensitivity

Lifestyle trumps pills long-term: 5-10% weight loss halves diabetes risk, normalizes insulin in 60%.

Top Evidence-Based Plays:

1. Low-GI Diet: Swap refined carbs for fiber bombs (25-30g/day: oats, lentils, berries). Mediterranean style slashes IR 25%; plate rule: ½ veggies, ¼ protein, ¼ whole grains.
2. Exercise Combo: 150min moderate aerobic (brisk walk/cycle) + 2x resistance (weights/bodyweight). HIIT 3x/week accelerates GLUT4 to muscles – 30% sensitivity gain.
3. Sleep Mastery: 7-9hrs/night. <6hrs spikes cortisol/IR 40%; consistent rhythm stabilizes glucose.

4. Stress Tune: 10min daily mindfulness/breathing. Cuts HPA overdrive fueling IR.

Real-world: 2025 meta-analysis – combined interventions beat diet-alone by 2x for ovulation/IR.

Quick Start	Daily Action	4-Week Win
Breakfast	Oats + berries + nuts	Stable AM glucose
Move	30min walk + squats	↓ HOMA-IR 15%
Wind Down	No screens 1hr pre-bed	Better sleep/insulin

Your Next Move

PCOS-IR isn't destiny – it's data-driven. Start with diet audit + walk; track fasting insulin if possible.

Prediabetes + PCOS? Double motivation for these shifts – halve your risk today.

Next week: Inositols deep-dive – stacks, doses, real results.

Until then,
Prioritize sensitivity. Small systems tweaks compound.

Warmly,

Jackie

PCOS & Prediabetes Action Checklist

Insulin Resistance: Target the Root, Not Just Symptoms

By Jackie Laver

1. Awareness & Assessment Check

- I understand that insulin resistance drives most PCOS cases (even if I'm lean).
- I know my latest:
 - HbA1c
 - Fasting glucose
 - Fasting insulin (if available)
 - Lipids
 - I understand my PCOS phenotype (classic / lean / mixed).
 - I've discussed metabolic risk (not just cycles/fertility) with my clinician.

Goal: Shift from “hormone problem” thinking → “metabolic driver” action.

2. Reduce Insulin Load Daily

Plate Audit (Tick what you did today)

- My plate was:
 - ½ non-starchy vegetables
 - ¼ quality protein
 - ¼ whole-food carbohydrate
 - I hit ~25–30g fibre.
 - I avoided refined carbs at breakfast.
 - I paired carbs with protein and fat.

Focus: Lower post-meal insulin spikes → calm ovarian androgen drive.

3. Muscle = Glucose Disposal

- I completed 30 minutes of movement today (walk/cycle/swim).
- I did resistance work (bodyweight, bands, weights) 2x this week.
- I moved within 30 minutes after a carb-heavy meal.

Why: Muscle contraction pulls glucose without needing insulin.

4. Sleep & Cortisol Reset

- I protected 7–9 hours of sleep.
- I reduced screens 60 minutes before bed.
- I kept a consistent sleep/wake time.

Remember: <6 hours sleep can worsen insulin resistance by ~40%.

5. Stress & Nervous System Regulation

- I did 5–10 minutes of breathing, mindfulness, or grounding.
- I avoided “all-or-nothing” thinking about food today.
- I protected emotional bandwidth (said no where needed).

Why: Chronic cortisol amplifies insulin resistance.

6. Treatment Discussion (If Applicable)

- I've discussed metformin (500–2000mg) with my clinician if indicated.
 - I understand inositol dosing (myo- 2–4g + D-chiro 50–100mg).
 - I know GLP-1 medications may be considered if weight/metabolic risk is high.
 - I understand supplements are supportive — not replacements for lifestyle.
-



7. Track What Matters (4-Week Experiment)

Choose 1–2 metrics only:

- Morning fasting glucose
- Waist circumference
- Cycle regularity
- Energy levels
- Cravings intensity

Expected Wins in 4 Weeks:

- ↓ HOMA-IR ~10–20% (with combined changes)
 - More stable morning glucose
 - Improved cycle predictability
 - Reduced central fat accumulation
-

30-Day Insulin Sensitivity Commitment

- Walk daily
- Lift twice weekly
- Eat fibre first
- Sleep on schedule
- Regulate stress daily

Small metabolic shifts compound.



Systems Reminder

PCOS + Prediabetes is not a willpower failure.
It is a feedback loop.

Break the insulin loop → and hormones follow.

Newsletter References (APA 7th Edition)

Prosperi, S., & colleagues. (2025). Insulin resistance, metabolic syndrome and polycystic ovaries. *Frontiers in Endocrinology*.

<https://doi.org/10.3389/fendo.2025.1669716>

Sun, N., Sun, P., Sun, L., Sun, P., Qi, D., & Ma, H. (2026). Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. *PLoS ONE*, *21*(2), Article e0342158.

<https://doi.org/10.1371/journal.pone.0342158>

Kite, C., Lafferty, K., McKenna, J., Clark, C., Corbet, J., & McCarthy, H. (2025). Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. *Scientific Reports*, *15*, Article 26718.

<https://doi.org/10.1038/s41598-025-26718-2>

Li, Y., Zhang, X., & Wang, L. (2026). Precision targeted therapy for PCOS: Emerging drugs, translational challenges, and future opportunities. *Frontiers in Endocrinology*.

<https://pmc.ncbi.nlm.nih.gov/articles/PMC12839070/>

Wang, J., Liu, H., & Chen, Q. (2026). The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. *Frontiers in Endocrinology*.

<https://doi.org/10.3389/fendo.2025.1722649>

Teede, H. J., Misso, M. L., & Costello, M. F. (2025). The role of lifestyle interventions in PCOS management: A systematic review. *PMC Articles*.

<https://pmc.ncbi.nlm.nih.gov/articles/PMC11767734/>

Cioffi, I., Marra, F., & Pasanisi, F. (2025). Impact of lifestyle interventions on reproductive and metabolic outcomes in PCOS: A meta-analysis. *PubMed*, 39833063.

<https://pubmed.ncbi.nlm.nih.gov/39833063/>

Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J., Legro, R., Lizneva, D., Natterson-Horowitz, B., Teede, H. J., & Yildiz, B. O. (2025). Polycystic ovary syndrome in 2025—insights and innovations. *Fertility and Sterility*.

<https://doi.org/10.1016/j.fertnstert.2025.01.922>

